Dexcom reaffirms full-year forecast after topping quarterly estimates

April 30, 2026 4:53 PM EDT

Type 2 diabetes patient Adedotun Adebayo (15) registers his new Dexcom device, a continuous glucose monitoring system, at his home in Glenarden, Maryland, U.S., July 15, 2021. Picture taken July 15, 2021. REUTERS/Hannah Beier

April 30 (Reuters) - Medical device ‌maker Dexcom ​on ​Thursday reiterated its full-year revenue forecast after beating Wall Street estimates for quarterly results, helped by ‌strong demand for its continuous glucose monitors that ⁠track blood sugar levels.

Shares of the company were down 4.3% in ‌after-hours trading.

The company maintained its ‌expectations for annual revenue in the range of $5.16 billion to $5.25 billion. Analysts expect $5.23 billion, according to data compiled ​by LSEG.

Rising awareness of diabetes care, wider insurance coverage and a consumer shift towards finger-prick-free technology have fueled ⁠demand for continuous glucose monitors, intensifying competition among market leaders Dexcom, Medtronic and ​Abbott Laboratories.

Dexcom said on Thursday demand for its CGM devices remained healthy. During the quarter, it ​expanded the launch of the Dexcom ‌G7 15 Day sensor in the U.S., added new meal-logging features to the Stelo platform ⁠and shared new clinical data showing benefits for people with type 2 diabetes who are not using insulin.

The company reported quarterly ⁠revenue of $1.19 billion, up 15% year-over-year, compared with the analysts' consensus ​estimate of $1.18 billion.

On an adjusted basis, it posted a quarterly profit of 56 cents per share, above estimates of 47 cents per ‌share.

The Stelo device, Dexcom's over-the-counter CGM for adults who are not on insulin, marks Dexcom's ‌push into a broader consumer health market, targeting people with ⁠type 2 diabetes or ‌those looking to monitor ​blood glucose for keeping their health in check.

(Reporting by Padmanabhan Ananthan in Bengaluru; Editing by Sahal ‌Muhammed)



Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Reuters